<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-07-06" updated="2020-01-02">
  <drugbank-id primary="true">DB01362</drugbank-id>
  <name>Iohexol</name>
  <description>Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.</description>
  <cas-number>66108-95-0</cas-number>
  <unii>4419T9MX03</unii>
  <average-mass>821.1379</average-mass>
  <monoisotopic-mass>820.880309705</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A2414</ref-id>
        <pubmed-id>3896713</pubmed-id>
        <citation>Kawada TK: Iohexol and iopamidol: second-generation nonionic radiographic contrast media. Drug Intell Clin Pharm. 1985 Jul-Aug;19(7-8):525-9.</citation>
      </article>
      <article>
        <ref-id>A2415</ref-id>
        <pubmed-id>3882609</pubmed-id>
        <citation>Shaw DD, Potts DG: Toxicology of iohexol. Invest Radiol. 1985 Jan-Feb;20(1 Suppl):S10-3.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Xiu C. Wang, Steve A. Chamberlin, Ashok V. Bhatia, Gregg E. Robinson, John Hufnagel, "Process for the preparation of iohexol." U.S. Patent US5705692, issued December, 1985.</synthesis-reference>
  <indication>Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.</indication>
  <pharmacodynamics>Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.</pharmacodynamics>
  <mechanism-of-action>Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intrathecal administration into the subarachnoid space, diffusion of iohexol in the CSF allows the visualization of the subarachnoid spaces of the head and spinal canal. After intravascular administration, iohexol makes opaque those vessels in its path of flow, allowing visualization of the internal structures until significant hemodilution occurs.</mechanism-of-action>
  <toxicity>Non-ionic radiocontrast agents like iohexol are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.</toxicity>
  <metabolism/>
  <absorption>Small amounts are absorbed through the bladder via intravesical instillation. Following intrauterine instillation, the majority of the medium within the uterine cavity is discharged into the vagina immediately upon termination of procedure. However, any medium retained in the uterine or peritoneal cavity is absorbed systemically within 60 minutes. May not be absorbed for up to 24 hours if tubes are obstructed and dilated.</absorption>
  <half-life>Intrathecal half-life is 3.4 hours (mean). Intravascular is approximately 2 hours (with normal renal function).</half-life>
  <protein-binding/>
  <route-of-elimination>Iohexol is absorbed from cerebrospinal fluid (CSF) into the bloodstream and is eliminated by renal excretion. No significant metabolism, deiodination, or biotransformation occurs.</route-of-elimination>
  <volume-of-distribution>* 350-849 mL/kg</volume-of-distribution>
  <clearance>* 109 mL/min [Adult patients receiving 16-18 ml of iohexol (180 mgI/mL) by lumbar intrathecal injection]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as o-haloacetanilides. These are organic compounds containing an acetamide group conjugated to a phenyl group, which is in turn ortho-substituted with a halogen atom.</description>
    <direct-parent>O-haloacetanilides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Anilides</subclass>
    <alternative-parent>Acetamides</alternative-parent>
    <alternative-parent>Aryl iodides</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboximidic acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Iodobenzenes</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organoiodides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>P-haloacetanilides</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <substituent>Acetamide</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Aryl iodide</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboximidic acid</substituent>
    <substituent>Carboximidic acid derivative</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Iodobenzene</substituent>
    <substituent>O-haloacetanilide</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organoiodide</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>P-haloacetanilide</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="inn/usan">Iohexol</synonym>
    <synonym language="latin" coder="inn">Iohexolum</synonym>
    <synonym language="english" coder="">N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide</synonym>
  </synonyms>
  <products>
    <product>
      <name>Omnipaque</name>
      <labeller>GE Healthcare Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0407-1413</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>300 mg/1mL</strength>
      <route>Intrathecal; Intravascular; Intravenous; Oral; Rectal</route>
      <fda-application-number>NDA020608</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omnipaque</name>
      <labeller>GE Healthcare Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0407-1414</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-09-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>350 mg/1mL</strength>
      <route>Intravascular; Intravenous; Oral; Rectal</route>
      <fda-application-number>NDA020608</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omnipaque</name>
      <labeller>Ge Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code>0407-1401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>140 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018956</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omnipaque</name>
      <labeller>Ge Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code>0407-1411</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-07-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>180 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018956</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omnipaque</name>
      <labeller>Ge Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code>0407-1415</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>9 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA018956</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omnipaque</name>
      <labeller>Ge Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code>0407-1416</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>12 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA018956</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omnipaque</name>
      <labeller>Apothecary Shop Wholesale Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42852-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-01</started-marketing-on>
      <ended-marketing-on>2011-08-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>388.3 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018956</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omnipaque</name>
      <labeller>Apothecary Shop Wholesale Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42852-017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-06-01</started-marketing-on>
      <ended-marketing-on>2011-08-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>518 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018956</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omnipaque</name>
      <labeller>Apothecary Shop Wholesale Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42852-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-01</started-marketing-on>
      <ended-marketing-on>2011-08-31</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>647.1 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018956</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omnipaque</name>
      <labeller>Ge Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code>0407-1412</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>240 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018956</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Omnipaque 180</name>
      <labeller>Ge Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02172720</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-03-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subarachnoid</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Omnipaque 180 Liq Sar 388mg/ml</name>
      <labeller>Sanofi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02018098</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>1997-07-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Subarachnoid</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Omnipaque 240</name>
      <labeller>Ge Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02172739</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravascular; Subarachnoid</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Omnipaque 240 Liq IV Sar 518mg/ml</name>
      <labeller>Sanofi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02018101</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>1997-07-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous; Subarachnoid</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Omnipaque 300</name>
      <labeller>Ge Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02172747</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravascular; Subarachnoid</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Omnipaque 300 Liq IV Sar 647mg/ml</name>
      <labeller>Sanofi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02018128</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>1997-07-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous; Subarachnoid</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Omnipaque 350</name>
      <labeller>Ge Healthcare</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02172755</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intravascular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Omnipaque 350 Liq IV 755mg/ml</name>
      <labeller>Sanofi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02018136</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-12-31</started-marketing-on>
      <ended-marketing-on>1997-07-30</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Oraltag</name>
      <labeller>Interpharma Praha, a.s.</labeller>
      <ndc-id/>
      <ndc-product-code>54702-501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>For solution</dosage-form>
      <strength>4.5 g/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA205383</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Histodenz</name>
      <company>Sigma</company>
    </international-brand>
    <international-brand>
      <name>Nycodenz</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Omnipaque</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Oraltag</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque 180</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque 240</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque 300</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque 350</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque 300 Liq IV Sar 647mg/ml</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque 240 Liq IV Sar 518mg/ml</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque 350 Liq IV 755mg/ml</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
    <mixture>
      <name>Omnipaque 180 Liq Sar 388mg/ml</name>
      <ingredients>Iohexol</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>GE Healthcare Inc.</name>
      <url>http://www.gehealthcare.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Nycomed Inc.</name>
      <url>http://www.nycomed.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Omnipaque 300 mg/ml syringe</description>
      <cost currency="USD">1.08</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Omnipaque 350 mg/ml infu btl</description>
      <cost currency="USD">1.08</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Omnipaque 240 mg/ml cartridge</description>
      <cost currency="USD">1.77</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Omnipaque 300 mg/ml cartridge</description>
      <cost currency="USD">2.17</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Omnipaque 350 mg/ml cartridge</description>
      <cost currency="USD">2.29</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Omnipaque 210 mg/ml vial</description>
      <cost currency="USD">3.53</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Omnipaque 300 mg/ml vial</description>
      <cost currency="USD">4.82</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Omnipaque 180 mg/ml vial</description>
      <cost currency="USD">4.92</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Omnipaque 240 mg/ml vial</description>
      <cost currency="USD">5.34</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Myelo-kit 180 mg/ml</description>
      <cost currency="USD">62.19</cost>
      <unit>each</unit>
    </price>
    <price>
      <description>Omnipaque 140 mg/ml vial</description>
      <cost currency="USD">0.78</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Acids, Carbocyclic</category>
      <mesh-id>D000146</mesh-id>
    </category>
    <category>
      <category>Agents that reduce seizure threshold</category>
      <mesh-id/>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Benzoates</category>
      <mesh-id>D001565</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Contrast Media</category>
      <mesh-id>D003287</mesh-id>
    </category>
    <category>
      <category>Diagnostic Uses of Chemicals</category>
      <mesh-id>D064907</mesh-id>
    </category>
    <category>
      <category>Iodinated Contrast Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Iodobenzoates</category>
      <mesh-id>D007463</mesh-id>
    </category>
    <category>
      <category>Radiographic Contrast Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Roentgenography</category>
      <mesh-id>D011859</mesh-id>
    </category>
    <category>
      <category>Triiodobenzoic Acids</category>
      <mesh-id>D014283</mesh-id>
    </category>
    <category>
      <category>Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media</category>
      <mesh-id/>
    </category>
    <category>
      <category>X-Ray Contrast Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>X-Ray Contrast Media, Iodinated</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>140 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>180 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>240 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intrathecal; Intravascular; Intravenous; Oral; Rectal</route>
      <strength>300 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravascular; Intravenous; Oral; Rectal</route>
      <strength>350 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>388.3 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>518 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous</route>
      <strength>647.1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>12 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>9 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subarachnoid</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Subarachnoid</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravascular; Subarachnoid</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous; Subarachnoid</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravascular</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>For solution</form>
      <route>Oral</route>
      <strength>4.5 g/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V08AB02">
      <level code="V08AB">Watersoluble, nephrotropic, low osmolar X-ray contrast media</level>
      <level code="V08A">X-RAY CONTRAST MEDIA, IODINATED</level>
      <level code="V08">CONTRAST MEDIA</level>
      <level code="V">VARIOUS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>36:68.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk of a hypersensitivity reaction to Iohexol is increased when it is combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The therapeutic efficacy of Lorazepam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The therapeutic efficacy of Pregabalin can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The therapeutic efficacy of Butalbital can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The therapeutic efficacy of Phenytoin can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The therapeutic efficacy of Topiramate can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The therapeutic efficacy of Valproic acid can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The therapeutic efficacy of Trimethadione can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The therapeutic efficacy of Clobazam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The therapeutic efficacy of Secobarbital can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The therapeutic efficacy of Metharbital can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The therapeutic efficacy of Methohexital can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The therapeutic efficacy of Carbamazepine can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The therapeutic efficacy of Ethosuximide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The therapeutic efficacy of Thiopental can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The therapeutic efficacy of Paramethadione can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>The therapeutic efficacy of Clorazepic acid can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The therapeutic efficacy of Tizanidine can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The therapeutic efficacy of Riluzole can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The therapeutic efficacy of Ethotoin can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The therapeutic efficacy of Primidone can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The therapeutic efficacy of Diazepam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>The therapeutic efficacy of Phensuximide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>The therapeutic efficacy of Progabide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>The therapeutic efficacy of Tiagabine can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The therapeutic efficacy of Zonisamide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The therapeutic efficacy of Felbamate can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>The therapeutic efficacy of Zaleplon can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The therapeutic efficacy of Gabapentin can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The therapeutic efficacy of Clonazepam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>The therapeutic efficacy of Phenacemide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>The therapeutic efficacy of Thiamylal can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The therapeutic efficacy of Estazolam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The therapeutic efficacy of Amobarbital can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The therapeutic efficacy of Barbital can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>The therapeutic efficacy of Delorazepam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>The therapeutic efficacy of 7-Nitroindazole can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>The therapeutic efficacy of Valpromide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The therapeutic efficacy of Flunarizine can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The therapeutic efficacy of Ezogabine can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The therapeutic efficacy of Methsuximide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The therapeutic efficacy of Rufinamide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The therapeutic efficacy of Lacosamide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>The therapeutic efficacy of Remacemide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The therapeutic efficacy of Deramciclane can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>The therapeutic efficacy of Tramiprosate can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>The therapeutic efficacy of Gaboxadol can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>The therapeutic efficacy of Sulthiame can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The therapeutic efficacy of Perampanel can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>The therapeutic efficacy of Barbexaclone can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>The therapeutic efficacy of Beclamide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The therapeutic efficacy of Cannabidiol can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The therapeutic efficacy of Stiripentol can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>The therapeutic efficacy of Eslicarbazepine acetate can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The therapeutic efficacy of Doramectin can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The therapeutic efficacy of Tiletamine can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>The therapeutic efficacy of Brexanolone can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>The therapeutic efficacy of Etiracetam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>The therapeutic efficacy of Carisbamate can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>The therapeutic efficacy of Pheneturide can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>The therapeutic efficacy of Neocitrullamon can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The therapeutic efficacy of Medazepam can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>The therapeutic efficacy of Phenibut can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>The therapeutic efficacy of Ethadione can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>The therapeutic efficacy of Cannabidivarin can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The therapeutic efficacy of Cenobamate can be decreased when used in combination with Iohexol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of seizure can be increased when Iohexol is combined with Amifampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06637</drugbank-id>
      <name>Dalfampridine</name>
      <description>The risk or severity of seizure can be increased when Iohexol is combined with Dalfampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The risk or severity of seizure can be increased when Bupropion is combined with Iohexol.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-2.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>7.96e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>N1,N3-bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>iohexol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>821.1379</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>820.880309705</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C19H26I3N3O9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NTHXOOBQLCIOLC-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>199.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>148.84</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>60.37</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>11.73</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>174-180 C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-3.05</value>
      <source>HANSCH,C &amp; LEO,AJ (1985)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>8092</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7218</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>31709</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>3730</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506178</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01817</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>3599</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA450061</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Iohexol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1200455</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>